Who We Are
Dr. James A. Bannon, former President of Late Stage Development Services at Covance Inc., one of the pioneers and leaders in the Clinical Research Organization (CRO) industry, is IndiPharm’s Executive Chairman. Dr. Bannon has more than 25 years of experience in Clinical and Medical Research. His career has spanned virtually all aspects of clinical research including principal investigator, project manager and executive management. He has consistently built and led high performing teams resulting in high client satisfaction and significant repeat business.
Dr. Edward J. Brennan, former Director of Clinical Pharmacology and Discovery Medicine at GlaxoSmithKline (GSK), joined IndiPharm as President and CEO in early 2007. At GSK, Dr. Brennan was responsible for coordinating all clinical activities for external partners within GSK’s Center of Excellence in External Drug Discovery (CEEDD). Before joining GSK, Dr. Brennan held clinical development positions of increasing responsibility at Johnson & Johnson and Wyeth. Dr. Brennan has extensive experience across all phases of clinical development and across multiple therapeutic areas, including Oncology, Infectious Diseases, Immunology, and Critical Care.
IndiPharm was founded by Mr. Dilip Limaye, who has extensive experience as a senior advisor and consultant to organizations such as the World Bank, UNDP, International Finance Corporation, USAID, and other international funding agencies, as well as an entrepreneur who has participated in the establishment of a number of international organizations in a wide range of fields including energy efficiency, renewable energy, information technology (IT), and business process outsourcing (BPO). Most of these ventures have combined the establishment of a U.S. based organization for client interface and services, with an established Indian operation to execute projects and programs efficiently and effectively. Clients, through the U.S.-India interface, are provided global quality services, reductions in the time required to deliver the services, and substantial cost savings.
Having successfully and repeatedly implemented this business model of U.S.-India cooperation, Mr. Limaye recognized the exponential growth potential for clinical trials in India and created IndiPharm. He established the required capabilities both in the U.S. and India, making it possible for Western biotech and pharmaceutical companies to outsource clinical trials to India through IndiPharm.
IndiPharm’s Scientific Advisory Board includes three highly distinguished individuals: Dr. Shashank Joshi, Dr. Purvish Parikh, and Dr. Mark Strobeck .
IndiPharm’s operations in India are carried out through its wholly-owned subsidiary IndiPharm ( India ) Private Limited. IndiPharm has established the Indian Investigator Network (IIN) of ICH/GCP compliant clinical investigators who have extensive experience in a wide range of therapeutic areas.
|
